Messenger RNA – Page 19 – Communicable Diseases Research

Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis

COVID-19 백신의 효능, 면역원성 및 안전성: 체계적인 검토 및 메타 분석

Meta-Analysis

Published on 2021-10-112022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 변종, 임상, 진단, 치료기술,

[키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adenovirus adenovirus vector vaccine adenovirus vector vaccines analyzed article articles Chain Reaction clinical trial clinical trials confirmed case coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection COVID-19 vaccine COVID-19 vaccines Efficacy Efficacy and safety eligible evidence of fatigue immunogenicity inclusion criteria injection injection site Lancet Local local symptom Messenger RNA Meta-analysis moderate mRNA mRNA vaccine mRNA vaccines Neutralizing antibodies neutralizing antibody non-randomized observational studies observational study participant Participants Phase I phase III trial polymerase chain polymerase chain reaction prevalent randomized clinical trial randomized clinical trials RBDs receiving Receptor-binding domain receptor-binding domains reduction in reported Research respiratory reverse transcriptase Reverse transcriptase polymerase chain reaction review risk Safety SARS-CoV-2 searched second dose selected severe acute respiratory syndrome Coronavirus Side effect Symptom the vaccine the vaccines transcriptase vaccination Vaccine Vaccines variant
[DOI] 10.3389/fimmu.2021.714170 PMC 바로가기 [Article Type] Meta-Analysis

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors

BNT162b2-면역화된 SARS-CoV-1 생존자의 범-사베코바이러스 중화 항체

Article

Published on 2021-10-072022-09-11
Journal: The New England Journal of Medicine [Category] MERS, SARS, 변종, 진단,

A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study

PD-1/PD-L1 억제제로 치료받은 암 환자를 대상으로 한 BNT162b2 항-SARS-CoV-2 백신 전체 과정의 면역원성, 효능 및 안전성에 대한 스냅샷: 종단적 코호트 연구

Article

Published on 2021-10-012022-09-11
Journal: ESMO open [Category] MERS, SARS, 바이오마커, 진단,

[키워드] 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive administration anti-SARS-CoV-2 blood sample Blood samples BNT162b2 BNT162b2 anti-SARS-CoV-2 vaccine BNT162b2 vaccine Cancer cancer patient Cancer patients CD4 CD4+ CD4+ T follicular response CD8+ T-cell CD8+ T-cell response cell-mediated immune cellular response Complete coronavirus coronavirus disease coronavirus disease-2019 Course COVID-19 case COVID-19 cases demonstrated Efficacy and safety elicit elicited enrolled enzyme enzyme-linked immunospot assay Focusing follicular humoral IFN-γ Immune checkpoint inhibitors immune response inhibitor interferon interferon-γ interquartile range IQR knowledge longitudinal cohort study mandatory median Messenger RNA mononuclear cell naïve naïve subjects Neutralizing antibodies no difference no differences of BNT162b2 participant Patient patients PBMC PD-1/PD-L1 inhibitors Peripheral blood primary endpoint programmed cell death programmed cell death protein proportion Protein reached reported respiratory response SARS-CoV-2 SARS-CoV-2 neutralizing antibodies SARS-CoV-2 neutralizing antibody second dose severe acute respiratory syndrome Coronavirus significant increase significantly higher significantly increased Specific T-cell response spike-specific T-cell response subject subjects sustained T cells T-cell Response the primary endpoint treated undetectable vaccination vaccination schedule Vaccine
[DOI] 10.1016/j.esmoop.2021.100272 PMC 바로가기 [Article Type] Article

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients

Observational Study

Published on 2021-10-012022-10-05
Journal: American journal of kidney diseases : the official [Category] 임상,

[키워드] activated acute respiratory syndrome age analyzed antibody Antibody Response Antigen approaches association Barcelona baseline BNT162b2 CD4 cellular Cellular immune response cellular immunity cellular response characterized Clinical outcome comparable coronavirus coronavirus disease COVID-19 COVID-19 vaccines defined dialysis effective vaccine End-stage renal disease End-stage renal disease (ESRD) evaluate evaluated General population Health health authorities Hemodialysis high risk higher risk humoral Humoral response IgG IgG antibody IgG level immunization immunogenicity Immunosuppression Immunosuppressive treatment Infection kidney Laboratory Logistic Messenger RNA Moderna mRNA mRNA vaccine mRNA vaccines mRNA-1273 multicenter cohort study Multiple linear regression multivariable Patient patients patients treated Pfizer-BioNTech positive response proportion rationale receiving reported response SARS-CoV-2 SARS-CoV-2 vaccine secondary outcome Seroconversion seroconverted seronegative setting Spain study outcomes T cell tested the receptor-binding domain vaccination vaccine administration were used
[DOI] 10.1053/j.ajkd.2021.06.002 PMC 바로가기 [Article Type] Observational Study

Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

SARS-CoV-2에 대한 Pfizer mRNA 백신 2회 접종 후 염증성 류마티스 질환 환자의 질병 활성 및 체액 반응

Article

Published on 2021-10-012022-09-11
Journal: Annals of the rheumatic diseases [Category] MERS, SARS, 임상, 진단, 치료기술,

[키워드] (Abbott Abbott administration age antirheumatic agents Autoimmune Autoimmune diseases biological therapy blood sample Blood samples consecutive patients COVID-19 disease dose humoral Humoral response IgG IgG antibodies IgG antibody immunomodulating drug immunomodulating drugs immunomodulatory therapy Inflammatory majority Messenger RNA mounted mRNA mRNA vaccine Patient patients patients treated Pfizer receiving recruited remained reported rheumatic disease Rheumatic diseases rheumatology SARS-CoV-2 SARS-CoV-2 virus second dose second dose of vaccine second vaccination serology Side effect the SARS-CoV-2 the vaccine treated Trial vaccination Vaccine
[DOI] 10.1136/annrheumdis-2021-220503 PMC 바로가기 [Article Type] Article

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

자가면역 염증성 류마티스 질환 성인 환자 및 일반 인구에서 BNT162b2 mRNA COVID-19 백신의 면역원성과 안전성: 다기관 연구

Observational Study

Published on 2021-10-012022-09-12
Journal: Annals of the rheumatic diseases [Category] MERS, SARS, 임상, 진단,

[키워드] adverse event Autoimmune binding antibody unit biological therapy BNT162b2 mRNA BNT162b2 mRNA vaccine Control control group COVID-19 COVID-19 pandemic COVID-19 vaccine death defined Disease activity Efficacy evaluated Factor General population Glucocorticoids herpes zoster IgG IgG antibody IgG level immunogenic immunogenicity Inflammatory Major majority Messenger RNA methotrexate Mild MMF mRNA multicentre Older age Patient patients postvaccination Protein reduced remained rheumatic disease rituximab S1/S2 safety profile SARS-CoV-2 spike seronegative Seropositivity significantly significantly lower symptomatic case Treatment two-dose regimen vaccination Vaccine vaccine dose were assessed were measured
[DOI] 10.1136/annrheumdis-2021-220647 PMC 바로가기 [Article Type] Observational Study

Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination

Comparative Study

Published on 2021-10-012022-10-06
Journal: JAMA Cardiology [Category] SARS, 진단,

Detection of neutralizing anti-severe acute respiratory syndrome coronavirus 2 antibodies in patients with common variable immunodeficiency after immunization with messenger RNA vaccines

전령 RNA 백신 접종 후 공통 가변성 면역결핍증 환자에서 항중증급성호흡기증후군 코로나바이러스 2 항체 중화 검출

Article

Published on 2021-10-012022-09-11
Journal: Annals of allergy, asthma & immunology : official [Category] MERS, SARS, 진단, 치료기술,

[키워드] acute respiratory syndrome antibody coronavirus detection immunization immunodeficiency Messenger RNA Neutralizing Patient Vaccine
[DOI] 10.1016/j.anai.2021.07.026 PMC 바로가기 [Article Type] Article

Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination

BNT162b2 mRNA 백신 접종 후 SARS-CoV-2 감염 및 체액성 면역 반응 이후 경과 시간

Research paper

Published on 2021-09-242022-09-12
Journal: EBioMedicine [Category] MERS, SARS, 진단,

[키워드] Adjustment age Antibody binding binding binding antibody BNT162b2 BNT162b2 mRNA vaccination comparable Corona COVID-19 development finding foundation funding healthcare humoral humoral immune response immune response increase in individual Infection IQR median Melinda Gate Messenger RNA mRNA mRNA vaccination Netherland neutralisation neutralisation titre Neutralisation titres neutralising nine not affect organization outcome participant SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 vaccines second vaccination serum IgG Sex tested time uninfected uninfected participant vaccination Vaccinations Vaccine vaccine dose
[DOI] 10.1016/j.ebiom.2021.103589 PMC 바로가기 [Article Type] Research paper

Does reactogenicity after a second injection of the BNT162b2 vaccine predict spike IgG antibody levels in healthy Japanese subjects?

Research Article

Published on 2021-09-202022-10-28
Journal: PLoS ONE [Category] COVID-19, SARS,